Prof. Mark Middleton appointed to Physiomics SAB

RNS Number : 9498U

Physiomics PLC

04 August 2015

 

Physiomics plc

("Physiomics") or ("the Company")

Professor Mark Middleton appointed to Physiomics SAB

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it has appointed Professor Mark Middleton to its Scientific Advisory Board.  Professor Middleton is Professor of Experimental Cancer Medicine in the Department of Oncology of the University of Oxford.  He is an eminent clinician with highly relevant clinical experience.

Mark is the Lead Cancer Clinician for the Oxford University Hospitals NHS Trust and deputy director of the Cancer Research UK Oxford Centre.  He directs the EPCTU and the Cancer Theme of the NIHR Biomedical Research Centre.  Mark studied medicine at Cambridge and Oxford and trained in medical oncology at the Christie Hospital.  He is a member of the International Melanoma Working Group and of the NCRI Melanoma Clinical Studies Group. Mark leads several clinical trials in the national portfolio, with an emphasis on early phase trials of new drugs or drug combinations.

The directors believe that Mark's experience as a clinical oncologist will be invaluable, particularly as the Company seeks to access the stratified and personalised medicine market.

Dr Mark Chadwick, CEO of Physiomics, commented:

"We are delighted to welcome Professor Middleton to our SAB. His undoubted knowledge and expertise will be invaluable to Physiomics as we look to increase the number of clinical projects we undertake and also seek to address the emerging market of stratified and personalised medicine for cancer treatment."

Enquiries:

Physiomics plc                                                  

Dr Mark Chadwick, CEO

[phone]

WH Ireland Limited (broker/nomad)

Katy Mitchell

[phone]

About Physiomics plc

Physiomics (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. 80-90 per cent of all clinical drug candidates fail to reach the market and estimates show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as $242 million, from the current estimate of around $800 million¹.

Physiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. Physiomics has created detailed mathematical models incorporating the most important molecular events taking place during the human cell cycle and apoptosis processes. The company's SystemCell® technology enables the simulation of populations of "virtual cells". The company has also developed a "Virtual Tumour" model to simulate the effect of anti-cancer drugs on tumour growth. The models are used to optimise compound design and to design drug schedules and combination therapies.

Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in 2004. For further information, please visit www.physiomics-plc.com

SystemCell® is a registered trademark of Physiomics plc

¹Tufts Centre Impact Report 2002

 

END

 

 

BOAPKNDBABKDNFK